Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

Abstract The efficacy and safety of chidamide, a new subtype-selective histone deacetylase (HDAC) inhibitor, have been demonstrated in a pivotal phase II clinical trial, and chidamide has been approved by the China Food and Drug Administration (CFDA) as a treatment for relapsed or refractory periphe...

Full description

Bibliographic Details
Main Authors: Yuankai Shi, Bo Jia, Wei Xu, Wenyu Li, Ting Liu, Peng Liu, Weili Zhao, Huilai Zhang, Xiuhua Sun, Haiyan Yang, Xi Zhang, Jie Jin, Zhengming Jin, Zhiming Li, Lugui Qiu, Mei Dong, Xiaobing Huang, Yi Luo, Xiaodong Wang, Xin Wang, Jianqiu Wu, Jingyan Xu, Pingyong Yi, Jianfeng Zhou, Hongming He, Lin Liu, Jianzhen Shen, Xiaoqiong Tang, Jinghua Wang, Jianmin Yang, Qingshu Zeng, Zhihui Zhang, Zhen Cai, Xiequn Chen, Kaiyang Ding, Ming Hou, Huiqiang Huang, Xiaoling Li, Rong Liang, Qifa Liu, Yuqin Song, Hang Su, Yuhuan Gao, Lihong Liu, Jianmin Luo, Liping Su, Zimin Sun, Huo Tan, Huaqing Wang, Jingwen Wang, Shuye Wang, Hongyu Zhang, Xiaohong Zhang, Daobin Zhou, Ou Bai, Gang Wu, Liling Zhang, Yizhuo Zhang
Format: Article
Language:English
Published: BMC 2017-03-01
Series:Journal of Hematology & Oncology
Subjects:
Chidamide
Peripheral T cell lymphoma
Treatment
Chemotherapy
Online Access:http://link.springer.com/article/10.1186/s13045-017-0439-6

Internet

http://link.springer.com/article/10.1186/s13045-017-0439-6

Similar Items